{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:17:09Z","timestamp":1772039829081,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019266","name":"GlaxoSmithKline Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ygyno.2024.03.002","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T23:30:00Z","timestamp":1710459000000},"page":"25-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer"],"prefix":"10.1016","volume":"183","author":[{"given":"Paul","family":"Gass","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falk C.","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"H\u00e4berle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Katharin","family":"Theuser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"Boehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Kimmig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Reinthaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Hilpert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phlipp","family":"Harter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius","family":"Emons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Hein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias W.","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrik","family":"P\u00f6schke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2024.03.002_bb0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.mcna.2015.01.003","article-title":"Cervical cancer prevention: immunization and screening 2015","volume":"99","author":"Thaxton","year":"2015","journal-title":"Med. Clin. North Am."},{"issue":"3","key":"10.1016\/j.ygyno.2024.03.002_bb0010","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00404-021-05986-z","article-title":"Human papilloma virus genotype distribution in women with premalignant or malignant lesions of the uterine cervix","volume":"304","author":"Stuebs","year":"2021","journal-title":"Arch. Gynecol. Obstet."},{"issue":"2","key":"10.1016\/j.ygyno.2024.03.002_bb0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/a-1671-2158","article-title":"Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032\/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and Therapy","volume":"82","author":"Beckmann","year":"2022","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"2","key":"10.1016\/j.ygyno.2024.03.002_bb0020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/a-1671-2446","volume":"82","author":"Fehm","year":"2022","journal-title":"Geburtshilfe Frauenheilkd."},{"issue":"8","key":"10.1016\/j.ygyno.2024.03.002_bb0025","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1055\/a-1934-1686","article-title":"Standardized procedures for patients with dysplasia and other diseases of the cervix, vulva, and vagina at a certified dysplasia unit prior to the introduction of the organized cervical cancer screening program","volume":"83","author":"Schulmeyer","year":"2023","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"10.1016\/j.ygyno.2024.03.002_bb0030","author":"Krebs in Deutschland f\u00fcr 2017\/2018"},{"issue":"47","key":"10.1016\/j.ygyno.2024.03.002_bb0035","first-page":"806","article-title":"The diagnosis, treatment, and aftercare of cervical carcinoma","volume":"118","author":"Beckmann","year":"2021","journal-title":"Dtsch. Arztebl. Int."},{"issue":"20","key":"10.1016\/j.ygyno.2024.03.002_bb0040","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMoa1806395","article-title":"Minimally invasive versus abdominal radical hysterectomy for cervical Cancer","volume":"379","author":"Ramirez","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9\u201310","key":"10.1016\/j.ygyno.2024.03.002_bb0045","first-page":"1549","article-title":"cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the gynecologic oncology group","volume":"63","author":"Thigpen","year":"1979","journal-title":"Cancer Treat. Rep."},{"issue":"4","key":"10.1016\/j.ygyno.2024.03.002_bb0050","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/1097-0142(19810815)48:4<899::AID-CNCR2820480406>3.0.CO;2-6","article-title":"Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"48","author":"Thigpen","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2024.03.002_bb0055","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-4615-5447-9_4","article-title":"Advances in the treatment of cervical cancer","volume":"95","author":"Moore","year":"1998","journal-title":"Cancer Treat. Res."},{"issue":"1","key":"10.1016\/j.ygyno.2024.03.002_bb0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.1997.15.1.165","article-title":"Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"15","author":"Omura","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2024.03.002_bb0065","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2004.04.170","article-title":"Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"22","author":"Moore","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.03.002_bb0070","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ygyno.2003.11.019","article-title":"Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma","volume":"92","author":"Tiersten","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"21","key":"10.1016\/j.ygyno.2024.03.002_bb0075","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study","volume":"23","author":"Long","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.ygyno.2024.03.002_bb0080","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.03.002_bb0085","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00280-004-0814-1","article-title":"Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I\/II study","volume":"54","author":"Stathopoulos","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.03.002_bb0090","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ygyno.2012.01.047","article-title":"Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study","volume":"125","author":"Chase","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.03.002_bb0095","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2307\/2533441","article-title":"Evaluation of experiments with adaptive interim analyses","volume":"50","author":"Bauer","year":"1994","journal-title":"Biometrics"},{"issue":"8","key":"10.1016\/j.ygyno.2024.03.002_bb0100","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"10103","key":"10.1016\/j.ygyno.2024.03.002_bb0105","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ygyno.2024.03.002_bb0110","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505","volume":"33","author":"Kitagawa","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2024.03.002_bb0115","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.ygyno.2024.03.002_bb0120","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of Pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.03.002_bb0125","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2024.03.002_bb0130","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2024.03.002_bb0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1479-5876-9-77","article-title":"Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy","volume":"9","author":"Alagkiozidis","year":"2011","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2024.03.002_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032542","article-title":"Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells","volume":"7","author":"Wan","year":"2012","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.ygyno.2024.03.002_bb0145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/1547691X.2012.693547","article-title":"Combined treatment of human colorectal tumor cell lines with chemotherapeutic agents and ionizing irradiation can in vitro induce tumor cell death forms with immunogenic potential","volume":"9","author":"Frey","year":"2012","journal-title":"J. Immunotoxicol."},{"issue":"6","key":"10.1016\/j.ygyno.2024.03.002_bb0150","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with Cemiplimab in recurrent cervical Cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.03.002_bb0155","doi-asserted-by":"crossref","first-page":"S1276","DOI":"10.1016\/j.annonc.2023.10.029","article-title":"LBA9 innovaTV 301\/ENGOT-cx12\/GOG-3057: a global, randomized, open-label, phase III study of tisotumab vedotin vs investigator\u2019s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer","volume":"34","author":"Vergote","year":"2023","journal-title":"Ann. Oncol."},{"issue":"31","key":"10.1016\/j.ygyno.2024.03.002_bb0160","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of Nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II CheckMate 358 trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2024.03.002_bb0165","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.annonc.2023.10.694","volume":"34","author":"Oaknin","year":"2023","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T11:07:18Z","timestamp":1717499238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824001410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":33,"alternative-id":["S0090825824001410"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.03.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}